molecules of the month


oral prostaglandin F receptor GCPR antagonist

to treat IPF, in vivo efficacy in fibrosis model

from ~3M cmpd cell-based HTS and opt.

J. Med. Chem., Oct. 22, 2020 issue

Bayer AG, Wuppertal, DE

Structure of BAY-6672, a potent, selective and orally bioavailable prostanoid FP receptor antagonist
1 min read

BAY-6672 (Bayer oral in vivo prostaglandin F receptor GCPR antagonist)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: